Nov 08, 2018
Sangamo Therapeutics Reports Third Quarter 2018 Financial Results
Nov 06, 2018
Sangamo Therapeutics Announces Participation At Upcoming Investor Conferences
Nov 01, 2018
Sangamo Therapeutics Announces Third Quarter 2018 Conference Call and Webcast
Sep 24, 2018
Sangamo Therapeutics Announces Participation At Upcoming Investor and Industry Conferences
Sep 05, 2018
Sangamo Announces 16 Week Clinical Results Including Reductions In Glycosaminoglycans In Phase 1/2 Trial Evaluating SB-913, A Zinc Finger Nuclease Genome Editing Treatment For MPS II (Hunter Syndrome)
Aug 30, 2018
Sangamo Therapeutics Announces Conference Call To Review SB-913 CHAMPIONS Study Data And Participation At Upcoming Investor Conferences
Aug 10, 2018
Sangamo Therapeutics Announces Presentation At The 2018 Wedbush PacGrow Healthcare Conference
Aug 08, 2018
Sangamo Therapeutics Reports Second Quarter 2018 Financial Results
Aug 02, 2018
Sangamo Therapeutics Announces Second Quarter 2018 Conference Call and Webcast
Jul 31, 2018
Sangamo Announces Preliminary Data From Champions Study Evaluating SB-913, An Investigational Genome Editing Treatment For MPS II, To Be Presented September 5th At SSIEM 2018 Symposium
Jul 27, 2018
Sangamo To Host Educational Webcast With Hunter Syndrome (MPS II) Expert, Joseph Muenzer, M.D., Ph.D.
Jul 23, 2018
Sangamo Announces Treatment Of First Patient In Phase 1/2 Clinical Trial Evaluating SB-318 Investigational In Vivo Genome Editing Therapy For MPS I
Jul 23, 2018
Sangamo Therapeutics to Acquire TxCell
Jun 28, 2018
Sangamo Therapeutics Appoints Karen Smith to its Board of Directors
Jun 04, 2018
Sangamo Announces U.K. Authorization Of Clinical Trials Evaluating Zinc Finger Nuclease In Vivo Genome Editing Treatments SB-318 For MPS I And SB-913 For MPS II
May 08, 2018
Sangamo Therapeutics Reports First Quarter 2018 Financial Results
May 03, 2018
Sangamo Therapeutics Announces Senior Leadership Changes
May 01, 2018
Sangamo Therapeutics Announces Presentations At 2018 Annual Meeting Of The American Society Of Gene & Cell Therapy
Apr 30, 2018
Sangamo Therapeutics Announces Completion of Public Offering of Common Stock and Exercise in Full of Underwriters' Option to Purchase Additional Shares
Apr 25, 2018
Sangamo Therapeutics Announces Pricing of Public Offering of Common Stock